Invokana (canagliflozin) belongs to a new class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors. Normally, when a person eats, the body produces insulin to process sugar that enters the body. In people with Type 2 diabetes, this response no longer works the way it should, and they develop insulin resistance. Eventually, the pancreas cannot keep up with the demand for insulin and sugar levels rise to dangerous levels. Invokana and other SGLT2 inhibitors work by preventing sugar from being reabsorbed into the blood.